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Vinca alkaloids, vinblastine and vincristine
sulfate, have a variety of effects on cells in vivo
and in vitro (1-10). In low sublethal doses,
vinblastine and vincristine arrest cells in mitosis
(1-3) and prevent the formation and organi-
zation of the spindle microtubules (2, 3) . Ac-
cumulation of large proteinaceous crystals in
platelets (7), in tissue culture cells (8, 10), and
in cells of the nervous system (9) by exposure to
high doses of vinblastine and vincristine has been
reported. The presence of colchicine-binding
microtubular proteins in the vincristine- and
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927vinblastine-induced crystals is suggested by the
radioautographic labeling of the crystals in cul-
tured cells by colchicine- 3H (11) .
The association of a large number of ribosomes
and helical polyribosomes with the vincristine-
and vinblastine-induced crystals and with com-
plexes of electron-opaque granular material has
been recently reported (10, 12). In thin sections
a faint linearity is recognizable in the granular
material of the complexes, while in other planes
sections reveal tubular structures, 280 A in di-
ameter (similar to those seen in cross-sections of
the vinblastine-induced crystals), surrounded by
the granular material and the ribosomes. These
observations suggest that the ribosome-granular
material complexes are the probable sites for
the formation of the proteins of the crystals and
that the associated ribosomes and polyribosomes
are involved in their synthesis .
In human lymphoblasts exposed to high doses
of vinblastine and vincristine, the granular ma-
terial-ribosomal complexes (henceforth referred
to as ribosomal complexes) are usually large in
size and frequency and often show large rows
of associated helical polyribosomes (12) . In the
present investigation we have tried to explore
further the nature of these ribosomal complexes
by exposing human lymphoblasts and Earle's
L-929 fibroblasts in culture to some of the well-
known inhibitors of protein synthesis before and
concurrent with their exposure to high doses of
vinblastine and vincristine.
MATERIALS AND METHODS
Earle's L-929 mouse fibroblasts in monolayer cul-
tures and human lymphoblasts initially isolated from
the peripheral blood of a leukemic patient (CCRF-
CEM) and maintained in continuous suspension
cultures were used for the present study . Cell cul-
tures were exposed to vinblastine sulfate (Velban)
or vincristine (Oncovin) (5-10 ug/ml) for 15 min-
24 hr.
The following metabolic inhibitors were used be-
fore and during the exposure of cells to crystal-
inducing concentrations (5-10 pg/ml) of vinblastine
and vincristine. (a) Puromycin dihydrochloride
(Nutritonal Biochemicals Corporation, Cleveland,
Ohio) 0.25-10 ug/ml, 15 min-3 hr before the addi-
tion of vinblastine or vincristine (10 ug/ml) to the
culture media. (b) Cycloheximide (Acti-dione, Up-
john Co., Kalamazoo, Mich.) 1.5-10 ug/ml, 30
min-2 hr before the addition of vinblastine . (c)
p-fiuorophenylalanine (Nutritional Biochemicals




tion of vinblastine or vincristine. (d) Actinomycin
D (Lyovac Cosmegen, Merck, Sharp, and Dohme,
West Point, Pa.) 0.0625-1 jug/ml, 15 min-3 hr
before the addition of vinblastine or vincristine to
the culture media.
Leighton tube cover slips were washed in bal-
anced salt solution, fixed in acetic acid : alcohol
(1 :3), and stained with carbol-fuchsin and 1%
aqueous fast green FCF .
For electron microscope examination, cell buttons
were collected by light centrifugation and processed
by procedures described elsewhere (10).
OBSERVATIONS
In both the L cell fibroblasts and the CCRF-
CEM lymphoblasts exposed to vinblastine or
vincristine, a gradual increase in the number and
the size of the crystals was seen on continued in-
cubation in the drug-containing medium . Thus,
in cells exposed to vinblastine for 15 min no
crystals could be recognized, while in cells ex-
amined after 30-45 min a large number of small
crystals were present in the cytoplasm . In cells
incubated for as long as 24 hr with vinblastine,
unusually long crystals (some of them approxi-
mately 40 um long) were seen in the cytoplasm.
In electron micrographs crystals from cells ex-
posed to vinblastine for 24 hr were seen as large
arrays of parallel filaments occupying a major
part of the cytoplasm.
In addition to the crystals, cells exposed to
vinblastine or vincristine contained large cyto-
plasmic ribosomal complexes . In the CCRF-
CEM lymphoblasts exposed to vinblastine or
vincristine, unusually large ribosomal complexes
occurred more frequently than in L cells similarly
treated. Although ribosomal complexes were
absent in cells from cultures incubated for 15 min
with vinblastine or vincristine, large numbers of
ribosomal complexes could be recognized in
cells examined after 30 min of exposure . Fig. I
shows a large ribosomal complex in the cyto-
plasm of a CCRF-CEM cell exposed to vin-
blastine for 3 hr (arrows point to helical poly-
ribosomes). Although a faint linearity can be
recognized in the substructure of the granular
material, it lacks the prominent linear structure
seen in the crystals.
In some earlier studies it was reported that
puromycin, a strong inhibitor of protein syn-
thesis, did not prevent the formation of the
crystals in Earle's L cells exposed to vinblastine
or vincristine (8, 10) . In CCRF-CEM lympho-blasts incubated with puromycin (10 pg/ml)
for 30 min before the addition of vinblastine (10
µg/ml) for 3 hr to the medium, ribosomal ag-
gregates and helical polyribosomes were rarely
seen in the cytoplasm. These cells also had a re-
duced number of ribosomal complexes compared
to cells exposed to vinblastine alone. Fig. 2 shows
the fine structure of an unusually large ribosomal
complex in the cytoplasm of a CCRF-CEM cells
exposed to puromycin (10 µg/m1) for 30 min
before the addition of vinblastine (10 pg/ml)
for 3 hr. As seen in this electron micrograph, no
large aggregates of ribosomes or helical poly-
ribosomes (as seen in cells exposed to vinblastine
alone, Fig. 1) are seen in association with the
ribosomal complexes or in the cytoplasm of cells
exposed to puromycin.
Cycloheximide (like puromycin) does not
inhibit the initial formation of the crystals in
Earle's L cells. CCRF-CEM lymphoblasts ex-
posed to cycloheximide (5 µg/ml) and leucine-3H
before exposure to vinblastine (10 µg/ml) show
a marked inhibition in the uptake of the radio-
active label (unpublished observations) . Like
puromycin, cycloheximide did not prevent the
formation of the ribosomal complexes, but in cells
incubated with cycloheximide for 1 hr before the
addition of vinblastine for the next 3 hr, there
was an apparent reduction in the number of the
crystals and the ribosomal complexes compared
to cells from cultures exposed to vinblastine alone.
Although in cells exposed to cycloheximide and
vinblastine the crystals and the ribosomal com-
plexes were morphologically similar to those of
cells exposed to vinblastine alone, an apparent
reduction in the number of helical ribosomes as-
sociated with the complexes was evident in the
cycloheximide-treated cells. However, in con-
trast to cells exposed to puromycin, there was no
apparent breakdown of the ribosomal clusters and
polyribosomes in the cytoplasm of these cells.
Since the proteins forming the crystals and the
granular material associated with the ribosomal
complexes are supposedly similar to the micro-
tubular protein, and p-fluorophenylalanine (a
phenylalanine analogue) has been shown to in-
duce the formation of morphologically abnormal
cilia (13), we exposed CCRF-CEM cultures to
this analogue before the addition of vinblastine
to the medium. Compared to the inhibitory effect
of puromycin and cycloheximide on the forma-
tion of helical polyribosomes and ribosomal com-
plexes, this compound had no morphologically
detectable effect on either the crystals, the ribo-
somal complexes, or the associated helical poly-
ribosomes.
Pretreatment of CCRF-CEM cells and L
cells with 0.25-1 µg/ml of actinomycin D for 1
hr before the addition of vinblastine did not
prevent the formation of crystals. Similarly
exposure to low doses of actinomycin D (0.06
µg/ml) for 30 min before the exposure to vin-
blastine did not inhibit the formation of the
ribosomal complexes. Fig. 3 shows part of a
large complex from a CCRF-CEM cell exposed
to low doses of actinomycin D for 30 min before
the addition of vinblastine for the next 3 hr. Ar-
rows point to an unusually large polyribosome
in the middle of the complex. In cells exposed
to high doses of actinomycin D (0.1-1 µg/ml), a
definite inhibitory effect on the number and
size of the ribosomal complexes formed was
evident. In cells exposed to 0.1 µg/ml of actino-
mycin D for 3 hr before the addition of vinblastine,
only occasional ribosomal complexes with few
polyribosomes were seen. In cells exposed to
lµg/ml for a similar length of time, small ribo-
somal complexes were rarely seen.
DISCUSSION
As shown in the present study, crystals seen in cells
exposed to vinblastine for long periods of time are
considerably larger than those in cells exposed
to similar concentrations of vinblastine for shorter
lengths of time. There are two possible explana-
tions for this observation: either there is con-
tinued synthesis of the material for the crystals
in the presence of the alkaloid, or the large
crystals result from the aggregation and the align-
ment of smaller crystals . The submicroscopic ap-
pearance of the larger crystals suggests more a
continuity of structure than the aggregation of
smaller crystals. It is probable that newly syn-
thesized material is added on the surface of the
growing crystals initially composed of proteins
synthesized before the exposure of the cells to
the alkaloids. This view is supported by our
preliminary electron microscope radioauto-
graphic study with leucine3H showing in-
corporated label on the edges of the crystals.
The effect of cycloheximide in reducing the size
as well as the number of the crystals also supports
the above observations. Evidence from the present
studies and those reported earlier (8, 10, 11) makes
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FIGURE 1 A large ribosomal complex is shown in this electron micrograph of a lymphoblast exposed to
vinblastine for 3 hr . Arrows point to helical polyribosomes seen in association with the complex . X 45,310.
FIGURE 2 An unusually large ribosomal complex in a lymphoblast exposed to puromycin (10 .sg/ml)
for 30 min before the addition of vinblastine . In contrast to Fig. 1, large ribosomal aggregates or helical
polyribosomes are rarely seen in puromycin-treated cells . X 30,720.
FIGURE 3 Part of a large ribosomal complex from a lymphoblast exposed to actinomycin D (0.06 µg/ml)
for 30 min before the addition of vinblastine for 5 hr . Arrows point to an unusually large helical ribosomal
configuration. X 54,500.it probable that vinblastine-induced crystals are
formed not only from the material synthesized
by the cells before their exposure to vinblastine,
but also from additional material synthesized in
the presence of the alkaloid .
As described earlier (12) and seen in the present
study, in the human leukemic lymphoblasts
(CCRF-CEM) the ribosomal complexes not only
are more frequent but also are very long in size .
On the basis of a faint linearity recognizable in
the granular material, the presence of occasional
tubular cross-sections, and the association of ribo-
somes and polyribosomes with both the complexes
and the crystals, it is probable that the material
associated with the ribosomal complexes is similar
to that forming the crystals and that the com-
plexes are the sites for the synthesis of the crystal-
line material. However, in view of the recent
demonstration (14) that vinblastine can precipi-
tate structural proteins other than the micro-
tubule proteins, it is probable that some of
the complexes are formed from proteins other
than those of the microtubular variety .
None of the various protein synthesis inhibitors
used in the present study completely prevented
the formation of the ribosomal complexes . Puro-
mycin has been shown to inhibit protein synthesis
by forming a peptidyl-puromycin complex (15,
16), and disaggregation of polyribosomes in vivo
and in vitro by puromycin has been recently
demonstrated (see 17 for references). As seen in
the present study, cells exposed to puromycin
before their exposure to vinblastine show very
few ribosomal aggregates and helical polyribo-
somes in the cytoplasm and in association with
the ribosomal complexes. Although the complexes
in puromycin-treated cells are smaller in size
and fewer in number, this protein synthesis in-
hibitor does not completely prevent their forma-
tion.
Cycloheximide, a strong inhibitor of protein
synthesis, acts by preventing the transfer of amino
acids from the sRNA to the nascent polypeptide
chain (18, 19). In contrast to puromycin, cyclo-
heximide blocks the "read out" process, prevent-
ing the breakdown of the polyribosomes (or
ergosomes) and inhibiting the amino acid in-
corporation (18) . In the present study, cells
exposed to cycloheximide had fewer numbers of
ribosomal complexes, but in contrast to puro-
mycin there was no breakdown of the ribosomal
masses or helical polyribosomes into individual
ribosomes either in the cytoplasm or in association
with the ribosomal complexes. Similarly, actino-
mycin D in lower doses did not prevent the for-
mation of the complexes, while in higher doses
there was a distinct reduction in the size and num-
ber of the complexes. From these observations,
one can probably postulate that in the presence
of low doses of vinblastine there is continued
synthesis of material, but binding of the alkaloid
to the nascent polypeptide chain causes a freezing
of this metabolic process as manifested by the
shape of the ribosomal complexes. Protein syn-
thesis inhibitors used in the present study can
stop this synthesis (as seen in the reduced number
of complexes) but do not effect the precipitation
by vinblastine of the complexes which were al-
ready engaged in the synthesis. Needless to say,
further work is needed to assess the validity of
this hypothesis.
SUMMARY
A gradual increase in the size and the number of
vinblastine-induced crystals is seen in Earle's
L cell fibroblasts and human lymphoblasts (CCRF-
CEM) exposed to this antitumor alkaloid for 24
hr. Besides the crystals, a large number of ribo-
somal-granular material complexes are seen in
CCRF-CEM cells incubated with vinblastine .
In cells incubated with puromycin and cyclo-
heximide before the addition of vinblastine to the
medium, a reduction in the number and size of
the ribosomal complexes was seen . In puromycin-
treated cells disaggregation of ribosomal clusters
and helical polyribosomes was evident. No
morphologically detectable effect on the crystals
or the ribosomal complexes of cells incubated with
p-fluorophenylalanine was seen . Actinomycin D
at high doses had a definite inhibitory effect on
the number and size of these ribosomal com-
plexes.
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